As lawmakers and industry groups seek to get a handle on U.S. drug shortages, a new white paper from German market analytics firm QYOBO supports the thesis that disproportionately low prices for generic medicines can make it difficult for drugmakers to keep supplies afloat.
PRINCETON, N.J., July 15, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug...
MALVERN, Pa., July 15, 2024 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) announced today the launch of tiopronin delayed-release tablets, a generic version of Travere Therapeutics' THIOLA EC®.
Alembic Pharmaceuticals Limited (Alembic) announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Selexipag for Injection, 1,800 mcg/vial.
Pharmaceutical companies face a looming patent cliff over the next several years, as generic rivals could erode sales of some of the industry’s best-selling medicines. For some drugmakers, copycat competitors are already on the doorstep.
Indian pharma companies faked generic viagra data to gain approval, finds US FDA
Shares of Zydus Lifesciences touched 52-week high of Rs 1,203.20 in the early trade on July 11, riding on the final approval from the United States Food and Drug Administration (USFDA) to market a key drug used to treat chronic heart failure.
YARAL Pharma Now the Exclusive Supplier of Authorized Generic Levothyroxine Sodium Capsules in the U.S. Market
Global pharma major Lupin Limited (Lupin) announced that it has received tentative approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application for empagliflozin, linagliptin and metformin hydrochloride extended-release (ER) tablets, 5 mg/2.5 mg/1,000 mg, 10 mg/5 mg/1,000 mg, 12.5 mg/2.5 mg/1,000 mg, and 25 mg/5 mg/1,000 mg, to market a generic equivalent of Trijardy XR tablets, 5 mg/2.5 mg/1,000 mg, 10 mg/5 mg/1,000 mg, 12.5 mg/2.5 mg/1,000 mg, and 25 mg/5 mg/1,000 mg, of Boehringer Ingelheim Pharmaceuticals, Inc. This product will be manufactured at Lupin’s Pithampur facility in India.